285 related articles for article (PubMed ID: 24958166)
1. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
2. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
[TBL] [Abstract][Full Text] [Related]
3. Timing and risk factors for clinical fractures among postmenopausal women: a 5-year prospective study.
van Geel AC; Geusens PP; Nagtzaam IF; Schreurs CM; van der Voort DJ; Rinkens PE; Kester AD; Dinant GJ
BMC Med; 2006 Oct; 4():24. PubMed ID: 17029622
[TBL] [Abstract][Full Text] [Related]
4. Independent predictors of all osteoporosis-related fractures among healthy Saudi postmenopausal women: the CEOR Study.
Rouzi AA; Al-Sibiani SA; Al-Senani NS; Radaddi RM; Ardawi MS
Bone; 2012 Mar; 50(3):713-22. PubMed ID: 22178778
[TBL] [Abstract][Full Text] [Related]
5. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool.
Trémollieres FA; Pouillès JM; Drewniak N; Laparra J; Ribot CA; Dargent-Molina P
J Bone Miner Res; 2010 May; 25(5):1002-9. PubMed ID: 20200927
[TBL] [Abstract][Full Text] [Related]
6. Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study.
Sornay-Rendu E; Munoz F; Duboeuf F; Delmas PD
J Bone Miner Res; 2005 Nov; 20(11):1929-35. PubMed ID: 16234965
[TBL] [Abstract][Full Text] [Related]
7. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for clinical fractures among postmenopausal women: a 10-year prospective study.
van Geel TA; Geusens PP; Nagtzaam IF; van der Voort DJ; Schreurs CM; Rinkens PE; Dinant GJ
Menopause Int; 2007 Sep; 13(3):110-5. PubMed ID: 17785036
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for perimenopausal fractures: a prospective study.
Huopio J; Kröger H; Honkanen R; Saarikoski S; Alhava E
Osteoporos Int; 2000; 11(3):219-27. PubMed ID: 10824237
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women.
Antoniucci DM; Sellmeyer DE; Cauley JA; Ensrud KE; Schneider JL; Vesco KK; Cummings SR; Melton LJ;
J Bone Miner Res; 2005 May; 20(5):741-7. PubMed ID: 15824846
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
14. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Lau YT; Ahmed NN
Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
Abrahamsen B; Vestergaard P
Bone; 2013 Nov; 57(1):269-71. PubMed ID: 23973557
[TBL] [Abstract][Full Text] [Related]
16. Risk factors predicting fractures in early postmenopausal women.
Pfister AK; Welch CA; Emmett MK; Sheets NW
W V Med J; 2013; 109(3):8-12, 14-5. PubMed ID: 23798274
[TBL] [Abstract][Full Text] [Related]
17. The relationship between back pain and future vertebral fracture in postmenopausal women.
Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
[TBL] [Abstract][Full Text] [Related]
18. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Targownik LE; Lix LM; Leung S; Leslie WD
Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
[TBL] [Abstract][Full Text] [Related]
19. Hot flushes, bone mineral density, and fractures in older postmenopausal women.
Huang A; Grady D; Blackwell T; Bauer D
Obstet Gynecol; 2007 Apr; 109(4):841-7. PubMed ID: 17400844
[TBL] [Abstract][Full Text] [Related]
20. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
